These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25715778)

  • 41. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
    Zavodovskaya R; Liao AT; Jones CL; Yip B; Chien MB; Moore PF; London CA
    Am J Vet Res; 2006 Apr; 67(4):633-41. PubMed ID: 16579756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [In vitro chemosensitivity test with several antitumor agents against eight malignant brain tumor cell-lines].
    Mabuchi E; Shimizu K; Yamada M; Moriuchi S; Park K; Tamura K; Hayakawa T; Mogami H
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):233-8. PubMed ID: 1992917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.
    Lenz JA; Assenmacher CA; Costa V; Louka K; Rau S; Keuler NS; Zhang PJ; Maki RG; Durham AC; Radaelli E; Atherton MJ
    Cancer Immunol Immunother; 2022 Apr; 71(4):807-818. PubMed ID: 34415404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk Factors Associated with Development of Histiocytic Sarcoma in Bernese Mountain Dogs.
    Ruple A; Morley PS
    J Vet Intern Med; 2016 Jul; 30(4):1197-203. PubMed ID: 27160025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of expression and prognostic implications of transforming growth factor beta, programmed death-ligand 1, and T regulatory cells in canine histiocytic sarcoma.
    Murphy JD; Shiomitsu K; Milner RJ; Lejeune A; Ossiboff RJ; Gell JC; Axiak-Bechtel S
    Vet Immunol Immunopathol; 2023 Mar; 257():110560. PubMed ID: 36804838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RNA in situ hybridisation as a molecular diagnostic technique targeting IBA-1 and CD204 in canine histiocytic sarcoma.
    Engelien JL; Lejeune AT; Dark MJ; Milner RJ; Shiomitsu K
    Vet Med Sci; 2022 Jul; 8(4):1400-1408. PubMed ID: 35339118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative analysis of mRNA expression of surface antigens between histiocytic and nonhistiocytic sarcoma in dogs.
    Yamazaki H; Takagi S; Oh N; Hoshino Y; Hosoya K; Okumura M
    J Vet Intern Med; 2014; 28(1):204-10. PubMed ID: 24428323
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility of the second-generation curcumin analogue RL71 in canine histiocytic sarcoma.
    Kelly B; Thamm D; Rosengren RJ
    Vet Res Commun; 2024 Feb; 48(1):563-568. PubMed ID: 37597087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of a two-base insertion mutation of the
    Asada H; Tomiyasu H; Goto-Koshino Y; Ohno K; Tsujimoto H
    Am J Vet Res; 2019 Jul; 80(7):680-688. PubMed ID: 31246118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
    Zhou J; Cheng SC; Luo D; Xie Y
    Biochem Biophys Res Commun; 2001 Feb; 280(5):1237-42. PubMed ID: 11162660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour.
    Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T
    Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327
    [TBL] [Abstract][Full Text] [Related]  

  • 52. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
    Aleskog A; Tobin G; Laurell A; Thunberg U; Lindhagen E; Roos G; Nilsson K; Nygren P; Sundström C; Höglund M; Larsson R; Rosenquist R
    Eur J Haematol; 2004 Dec; 73(6):407-11. PubMed ID: 15522062
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcoma.
    Asada H; Tani A; Sakuma H; Hirabayashi M; Matsumoto Y; Watanabe K; Tsuboi M; Yoshida S; Harada K; Uchikai T; Goto-Koshino Y; Chambers JK; Ishihara G; Kobayashi T; Irie M; Uchida K; Ohno K; Bonkobara M; Tsujimoto H; Tomiyasu H
    Sci Rep; 2023 May; 13(1):8512. PubMed ID: 37231193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas.
    Erich SA; Teske E
    Vet Comp Oncol; 2024 Sep; 22(3):322-339. PubMed ID: 38867335
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction.
    Yamazaki J; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2008 Dec; 126(3-4):321-31. PubMed ID: 18977540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of multidrug resistance in a canine lymphoma cell line.
    Uozurmi K; Nakaichi M; Yamamoto Y; Une S; Taura Y
    Res Vet Sci; 2005 Jun; 78(3):217-24. PubMed ID: 15766940
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior.
    Hedan B; Thomas R; Motsinger-Reif A; Abadie J; Andre C; Cullen J; Breen M
    BMC Cancer; 2011 May; 11():201. PubMed ID: 21615919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
    Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful treatment of pediatric histiocytic sarcoma using abbreviated high-risk leukemia chemotherapy.
    Heath JL; Burgett SE; Gaca AM; Jaffe R; Wechsler DS
    Pediatr Blood Cancer; 2014 Oct; 61(10):1874-6. PubMed ID: 24888336
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High drug efflux pump capacity and low DNA damage response induce doxorubicin resistance in canine hemangiosarcoma cell lines.
    Morita A; Aoshima K; Gulay KCM; Onishi S; Shibata Y; Yasui H; Kobayashi A; Kimura T
    Res Vet Sci; 2019 Dec; 127():1-10. PubMed ID: 31648115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.